Overview

Safety, Tolerability and PK Study of AK0529 in Healthy Human

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Ark Biosciences Inc.
Treatments:
Ziresovir